Kosiborod MS, Jhund P, Docherty KF, et al. - In this analysis, researchers investigated the effects of dapagliflozin on a broad range of health status outcomes, using the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failure and reduced ejection fraction. They evaluated KCCQ at randomization, 4 and 8 months. At baseline, 4,443 patients had available KCCQ (median KCCQ-TSS 77.1 [IQR 58.3-91.7]). They observed consistent effects of dapagliflozin vs placebo on reducing cardiovascular death or worsening HF across the range of KCCQ-TSS. They observed reduced cardiovascular death and worsening HF across the range of baseline KCCQ in addition to improved symptoms, physical function, and quality of life in patients with HFrEF in correlation to dapagliflozin receipt. Moreover, an increase in the proportion of patients experiencing at least small, moderate and large improvements in health status was observed with dapagliflozin receipt; these effects were clinically important.